Reform of Japan's NTP and its technical perspectives

Kekkaku

Volumn 79, Issue 10, 2004, Pages 587-604

  Mori, Toru ^a  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

Disease control; DOTS; Epidemiology; Future prediction; National Tuberculosis Programme

Indexed keywords

BCG VACCINATION; CASE FINDING; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CONFERENCE PAPER; DIRECTLY OBSERVED THERAPY; GOVERNMENT; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; JAPAN; LAW; MEDICAL SOCIETY; MULTIDRUG RESISTANCE; NATIONAL TUBERCULOSIS PROGRAM; PATIENT CARE; PREDICTION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; BCG VACCINE; CHEMOPREVENTION; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; DIRECTLY OBSERVED THERAPY; HEALTH CARE REFORM; HUMANS; INCIDENCE; JAPAN; NATIONAL HEALTH PROGRAMS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEROLOGIC TESTS; TUBERCULOSIS;

EID: 10044260673     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (70)

1. Mori T: Role of tuberculosis control technologies in health transition of the productive population. In: High Technology, Population Wealth and Health. Perspectives of Advanced Technology Science 2, Furukawa T ed, 1995, Maruzen Planet, 73-92.
2. Styblo K, Meijer P: Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle. 1976; 57: 17-43.
3. Orme IM, McMurray DN, Belisle JT: Tuberculosis vaccine development: Recent progress. Trends in Microbiology. 2001; 9: 115-118.
4. Reed SG, Alderson MR, Dalemans W, et al.: Prospects for a better vaccine against tuberculosis. Tuberculosis. 2003; 83: 213-219.
5. Anonymous: First US Tuberculosis vaccine trial in 60 years begins. NIH News. National Institute of Health, January 26, 2004.
6. Centers for Disease Control and Prevention: Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR. 2004; 53: 683-686.
7. American Thoracic Society/Centers for Disease Control and Prevention: Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Am J Respir Critical Care Med. 2000; 161 (4, Part 2): S221-S247.
8. Chan J, Flynn J: The immunological aspects of latency in tuberculosis. Clinical Immunology. 2004; 110: 2-12.
9. Seiler P, Ulrichs T, Bandermann S, et al.: Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. JID. 2003; 188: 1326-1331.
10. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, et al.: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glycoxylate shunt enzyme isocitrate lyase. Nature. 2000; 406: 735-738.
11. White MC, Gournis E, Kawamura M, et al.: Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco. Int J Tuberc Lung Dis. 2003; 7: 30-35.
12. Netherlands Tuberculosis Register. KNCV Tuberculosis Foundation: Index Tuberculosis 2000. Nederland/The Netherlands, The Hague, The Netherlands, 2003.
13. Jereb J, Etkind SC, Jogler OT, et al.: Tuberculosis contact examinations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis. 2003; 7 (suppl): s384-390.
14. Davidow AL, Mangura BT, Wolman MS, et al.: Workplace contact investigations in the United States. Int J Tuberc Lung Dis. 2003; 7 (suppl): s446-452.
15. Dubroniewski FA, Gibson A, Ruddy M, et al.: Evaluation and Utilization as a Public Health Tool of a National Molecular Epidemiological Tuberculosis Outbreak Database within the United Kingdom from 1997 to 2001. J Clin Microbiol. 2003; 41: 1861-1868.
16. Barnes PF, Cave MD: Molecular epidemiology of tuberculosis. N Engl J Med. 2003; 349 (12): 1149-56.
17. Braden CR, Templeton GL, Cave MD, et al.: Interpretation of restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from a state with a large rural population. J Infect Dis. 1997; 175: 1446-1452.
18. Lambregts-van Weezenbeek CS, Sebek MM, van Gerven PJ, et al.: Tuberculosis contact investigation and DNA fingerprint surveillance in the Netherlands: 6 years' experience with nation-wide cluster feedback and cluster monitoring. Int J Tuberc Lung Dis. 2003; 7 (Suppl): S463-470.
19. Behr MA, Warren SA, Salamon H, et al.: Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999; 353: 444-449.
20. Kulaga S, Behr M, Nguyen D, et al.: Diversity of Mycobacterium tuberculosis Isolates in an Immigrant Population: Evidence against a Founder Effect. Am J Epidemiol. 2004; 159 (5): 507-513.
21. Verver S, Warren RM, Munch Z, et al.: Proportion of tuberculosis transmission that takes place in households in a high-incidence area. Lancet, 2004; 363: 212-214.
22. Mori T, Sakatani M, Yamagishi F, et al.: Specific Detection of Tuberculosis Infection with an Interferon-gamma Based Assay Using New Antigens. Am J Respir Crit Care Med. 2004; 170: 59-64.
23. Streeton JA, Desem N, Jones SL: Sensitivity and specificity of a gamma Interferon blood test for tuberculosis infection. International J Tuberculosis Lung Dis. 1998; 2: 443-450.
24. Andersen P, Munk ME, Pollock JM, et al.: Specific immune-based diagnosis of tuberculosis. Lancet. 2000; 356: 1099-1104.
25. Chan ED, Heifets L, Iseman MD: Immunologic diagnosis of tuberculosis: a review. Tubercle Lung Dis. 2000; 80 (3): 131-140.
26. Talbot EA, Burgess DC, Hone NM, et al.: Tuberculosis serodiagnosis in a predominantly HIV-infected population of hospitalized patients with cough, Botswana, 2002. CID. 2004;39:e1-7.
27. WHO/IUATLD Global Working Group on Antituberculosis Drug Resistance Surveillance: Guidelines for Surveillance of Drug Resistance in Tuberculosis, World Health Organization, International Union against Tuberc, 1977.
28. Commission on Laboratory Accreditation, Am College of Pathologists: Laboratory Accreditation Program, Microbiology Checklist. http://www.cap.org/ apps/docs/laboratory_ accreditation/checklists/microbiology_june2001.pdf
29. Lienhardt C: From exposure to disease: The role of environmental factors in susceptibility and development of tuberculosis. Epidemiologic Reviews. 2001; 23: 288-301.
30. Rieder HL, Cauthen GM, Kelly GD, et al.: Tuberculosis in the United States. JAMA, 1989; 262: 385-389.
31. Bellamy R, Beyers N, McAdam KFWJ, et al.: Genetic susceptibility to tuberculosis in Africans: A genome-wide scan. PNAS. 2000; 97: 8005-8009.
32. Delgado JC, Baena A, Thim S, et al.: Ethnic-specific genetic associations with pulmonary tuberculosis. JID. 2002; 186: 1463-1468.
33. Abe T, Iinuma Y, Yokoyama M, et al.: NRAMP1 polymorphisms, susceptibility and clinical features of tuberculosis. J Infect. 2003; 46: 215-220.
34. Rossouw M, Nel HJ, Cooke GS, et al.: Association between tuberculosis and a polymorphic NFκB binding site in the interferon γ. Lancet. 2003; 361: 1871-1872.
35. Li CM, Campbell CM, Kumararatne DS, et al.: Association of a polymorphism in the P2X7 gene with tuberculosis in a Gambian population. JID. 2002; 186: 1458-1462.
36. Waaler HT: Prinsippene for den selektive skjermbildeundersokese. T norske Laegeforen. 1975; 95: 1072-1073.
37. Bjartveit K: Mass minature radiophotography in Norway, today and in the future. Scand J Respir Dis. 1972; (suppl) 80: 31-42.
38. http://www.who.int/tdr/diseases/tb/specimen.htm
39. Framework for effective tuberculosis control. WHO Global Tuberculosis Programme, 1994. WHO/TB/94.179.
40. http://www.tballiance.org
41. Stover CK, Warrener P, VanDevanter DR, et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000; 405: 962-966.
42. www.cdc.gov/nchstp/tb/tbtc
43. WHO Communicable Disease Cluster: Fixed-dose combination tablets for treatment of tuberculosis. WHO/CDC/CPC/TB/99.267.
44. Frieden TR, Sterling TR, Munsiff SS, et al.: Tuberculosis Lancet. 2003; 362: 887-899.
45. Stop TB Partnership: TB and Poverty. TB Resource Library. Version: 31 March, 2003.